Vertex Pharmaceuticals VRTX saw the following analyst ratings for the past quarter:
| quickly | bit bullish | Moody | bit bearish | recession | |
|---|---|---|---|---|---|
| overall rating | 3 | 3 | 2 | 0 | 0 |
| last 30d | 1 | 1 | 0 | 0 | 0 |
| 1m ago | 0 | 1 | 1 | 0 | 0 |
| 2m ago | 1 | 1 | 0 | 0 | 0 |
| 3m ago | 1 | 0 | 1 | 0 | 0 |
In the last 3 months, 8 analysts have offered 12-month price targets for Vertex Pharmaceuticals. The company’s average target price is $301.0 with a high of $365.00 and a low of $256.00.
Below is a summary of how these 8 analysts rated Vertex Pharmaceuticals over the last 3 months. The higher the number of bullish ratings, the more positive analysts rate the stock, and the higher the number of bearish ratings, the more negative analysts rate the stock.
This is an 8.43% increase from the current average price target of $277.60.
Ratings come from analysts or banking and financial systems experts who report for specific stocks or defined sectors (usually once a quarter for each stock). Analysts typically draw their information from company conference calls and meetings, financial statements, and interactions with key insiders to make their decisions.
Some analysts also offer forecasts for metrics such as growth forecasts, earnings, and revenue to provide further guidance on the stock. Investors using analyst ratings should note that this particular recommendation is human and may be subject to error.
This article was created by Benzinga’s Automated Content Engine and is editor-reviewed.
source
